Filing summary
Issuer discrepancy: The supplied filing is for Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), not Palvella Therapeutics, Inc. It is an annual Form 10-K for the fiscal year ended December 31, 2020, filed March 31, 2021; it does not provide standalone 2020 Q4 financial results.
Business context
Pieris is a clinical-stage biotechnology company developing Anticalin-based therapeutics, focused primarily on respiratory disease and immuno-oncology. Its lead programs are inhaled PRS-060/AZD1402 for asthma, partnered with AstraZeneca, and cinrebafusp alfa, a HER2/4-1BB bispecific for cancer. The company had no approved products or product-sale revenue.
Financial performance and liquidity
| Metric ($ millions, except per-share data) | 2020 | 2019 |
|---|---|---|
| Revenue | 29.3 | 46.3 |
| Research and development expense | 46.5 | 55.0 |
| General and administrative expense | 16.7 | 18.4 |
| Operating loss | (33.9) | (27.2) |
| Net loss | (37.2) | (25.5) |
| Net loss per share, basic and diluted | (0.68) | (0.56) |
| Operating cash used | (45.9) | (52.5) |
Revenue fell 36.6% year over year, primarily reflecting lower AstraZeneca and ASKA-related revenue and lower collaboration revenue; Seagen milestone revenue and Servier revenue partly offset the decline. All revenue came from collaborations, licenses and related services, not product sales. Net loss widened by $11.8 million. Management attributed the $3.6 million of other expense, net, mainly to U.S. dollar strength/foreign exchange effects and lower interest income; interest income was $0.5 million versus $1.7 million.
At year-end, cash and cash equivalents were $70.4 million, with no short-term investments remaining, versus $41.9 million of short-term investments and $62.3 million of cash at the prior year-end. Current assets were $75.7 million and current liabilities $22.1 million. Total liabilities were $74.0 million, including $35.9 million of noncurrent deferred revenue and $15.9 million of current operating lease liabilities; the balance sheet does not list borrowings at year-end. Stockholders’ equity was $31.0 million and accumulated deficit was $211.4 million. Investing activities provided $39.2 million, principally reflecting investment maturities net of purchases; financing activities provided $10.1 million, mainly from the ATM equity offering. The company reported no off-balance-sheet arrangements.
Material changes and developments
- R&D expense decreased $8.5 million, including lower immuno-oncology spending during the cinrebafusp alfa clinical hold and lower PRS-060/AZD1402 manufacturing costs. G&A expense decreased $1.7 million.
- Seagen generated $9.7 million of 2020 revenue, including a $5.0 million milestone and revenue recognized after an amendment completed obligations for its first target program. Servier discontinued two earlier-stage programs, reducing potential future milestones; the parties continued work on PRS-344 and PRS-352.
- The FDA placed cinrebafusp alfa Phase 1 studies on partial hold in July 2020 pending stability and compatibility work. The FDA lifted the hold in January 2021 after reviewing the company’s data.
- In March 2021, after year-end, Pieris reported a $13.0 million AstraZeneca milestone for initiation of the PRS-060/AZD1402 Phase 2a study and agreed to issue AstraZeneca $10.0 million of shares. Seagen also agreed to invest $13.0 million in Pieris. These are subsequent events, not year-end cash or revenue.
Outlook, risks and unusual items
- Management expected available funds to support operations for at least 12 months from the filing date, but noted estimates are uncertain and additional funding may be needed. The company expected continued losses and no product revenue for the foreseeable future, and anticipated financing through equity, partnerships, licensing or milestones.
- AstraZeneca’s global Phase 2a asthma study was expected to begin dosing in Q2 2021. Pieris planned a Phase 2 study of cinrebafusp alfa in HER2-positive gastric cancer in 2021, and expected to file an IND/CTA for PRS-344 in 2021. These are forward-looking plans, not reported outcomes.
- Key risks include clinical and regulatory failure, dependence on partners and milestone payments, the need for additional capital and potential dilution, competition, and reliance on third-party manufacturers without redundant supply commitments. COVID-19 had affected clinical and supply activities, including an inventory challenge for the asthma program that management said had been resolved.
- The 2020 financial statements received an unqualified audit opinion. The auditor identified accrued and prepaid clinical trial expenses as a critical audit matter because estimating costs incurred but not yet invoiced involves judgment. Management said material weaknesses in IT controls and revenue recognition controls identified in 2019 were remediated in 2020 and that controls were effective as of year-end; the auditor did not provide an internal-control audit opinion.
Important facts for investors to verify
- Confirm the intended issuer: this filing is Pieris Pharmaceuticals, not Palvella Therapeutics.
- Review the complete audited statements and notes for cash runway assumptions, deferred collaboration revenue, lease commitments, and the clinical-cost accrual estimate.
- Check subsequent filings for actual completion and proceeds of the AstraZeneca and Seagen share transactions, and for collection or accounting treatment of the $13.0 million AstraZeneca milestone.
- Verify current clinical status and data for PRS-060/AZD1402, cinrebafusp alfa and PRS-344, including whether planned study starts occurred and whether interim findings were confirmed.
- Assess future financing needs, dilution, partner program decisions, manufacturing capacity and any renewed regulatory or COVID-related delays.